BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17311738)

  • 1. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
    Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A; Esposito M; Schipani C; Chimenti S
    J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
    J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
    Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
    González-Chavez JR; Berlingeri-Ramos AC; Sánchez Casiano MA
    J Drugs Dermatol; 2005; 4(6):735-9. PubMed ID: 16302559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.